Lilly shells out $1.6B for immuno-oncology company Armo

Eli Lilly and Co. (NYSE:LLY) is acquiring Armo BioSciences Inc. (NASDAQ:ARMO) for $50 per share in cash, or about $1.6 billion. The price

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE